(R)-3-(5-cyanohexyl)-7,8-dihydro-8-ethoxymethyl-1-methyl-1H-imidazo[2,1-f]-purine-2,4(3H,6H)-dione | 444602-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (R)-3-(5-cyanohexyl)-7,8-dihydro-8-ethoxymethyl-1-methyl-1H-imidazo[2,1-f]-purine-2,4(3H,6H)-dione
• 英文别名: (2R)-6-[6-(ethoxymethyl)-4-methyl-1,3-dioxo-7,8-dihydropurino[7,8-a]imidazol-2-yl]-2-methylhexanenitrile
• CAS: 444602-98-6
• 化学式: C₁₈H₂₆N₆O₃
• 分子量: 374.443
• InChiKey: BBVJDGHEBFEVKT-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  94.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-3-(5-cyanohexyl)-7,8-dihydro-8-ethoxymethyl-1-methyl-1H-imidazo[2,1-f]-purine-2,4(3H,6H)-dione 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 (R)-3-(5-cyanohexyl)-7,8-dihydro-1-methyl-1H-imidazo[2,1-f]-purine-2,4(3H,6H)-dione
  参考文献：
  名称：

  TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES

  摘要：

  发现新型三环化合物对于治疗或预防受细胞因子内部信号传导影响的疾病或疾病相关症状或表现具有益处。

  公开号：

  US20020103211A1

文献信息

• Tricyclic compounds and their uses
  申请人：——

  公开号：US20030162801A1

  公开（公告）日：2003-08-28

  Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

  新型三环化合物被发现对治疗或预防受细胞因子内部信号传导影响的疾病或疾病症状或表现有用。
• Tricyclic fused xanthine compounds and their uses
  申请人：Cell Therapeutics, Inc.

  公开号：US06586429B2

  公开（公告）日：2003-07-01

  Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling. The compounds have the following formulas where R1, R2 and R3 are defined in the written description of the invention.

  新型三环化合物被发现对于治疗或预防受细胞因子内部信号传递影响的疾病或障碍相关的症状或表现非常有用。这些化合物具有以下公式，其中R1，R2和R3在发明的书面描述中有定义。
• Uses of tricyclic compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US07247630B2

  公开（公告）日：2007-07-24

  Novel tricyclic compounds are disclosed having the general structure of Formulas I or II: were R1, R2 and R3 are defined in the written description of the invention. The compounds are useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by intracellular cytokine signaling.

  本发明揭示了具有I或II式一般结构的新型三环化合物：其中R1、R2和R3在发明的书面描述中有定义。该化合物可用于治疗或预防由细胞内细胞因子信号传导影响的疾病或疾病表现的症状或表现。
• Tricyclic purine compounds and their analogs as inhibitors of cytokine signalling
  申请人：CELL THERAPEUTICS, INC.

  公开号：EP1690864A2

  公开（公告）日：2006-08-16

  Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

  新型三环化合物可用于治疗或预防与受细胞因子细胞内信号传导影响的疾病或紊乱有关的症状或表现。
• TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBIOTRS OF CYTOKINE SIGNALLING
  申请人：CELL THERAPEUTICS, INC.

  公开号：EP1347976A2

  公开（公告）日：2003-10-01